Inhaled corticosteroids for the treatment of COVID-19

Mona Bafadhel1, Rosa Faner2, Camille Taillé3, Richard E.K. Russell1, Tobias Welte4, Peter J. Barnes5 and Alvar Agustí6

1King’s Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK. 2CIBER Enfermedades Respiratorias, IDIBAPS, Barcelona, Spain. 3Department of Pulmonary Diseases, University Hospital Bichat-Claude Bernard, AP-HP Nord, University of Paris, Paris, France. 4Department of Pulmonary and Infectious Diseases, Hannover University School of Medicine, Hannover, Germany. 5National Heart and Lung Institute, Imperial College London, London, UK. 6Cátedra de Salud Respiratoria (University of Barcelona), Respiratory Institute (Hospital Clinic Barcelona), IDIBAPS and CIBERES, Barcelona, Spain.

Corresponding author: Mona Bafadhel (mona.bafadhel@kcl.ac.uk)

Shareable abstract (@ERSpublications)
Treatments are urgently needed to improve outcomes for patients with coronavirus disease 2019 (COVID-19) infection. This review summarises the evidence for the potential protective role of inhaled corticosteroids in preventing severe COVID-19 infection. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.

Cite this article as: Bafadhel M, Faner R, Taillé C, et al. Inhaled corticosteroids for the treatment of COVID-19. Eur Respir Rev 2022; 31: 220099 [DOI: 10.1183/16000617.0099-2022].

Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.

Introduction
The pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has placed an unprecedented burden on healthcare systems globally. The first reported human case of COVID-19 was in December 2019, and the outbreak has resulted in over 600 million cases of the disease and over 6 million deaths worldwide to 15 September 2022 [1, 2]. COVID-19 is a respiratory infection that in mild cases causes fever, persistent cough and shortness of breath, but in severe cases can cause serious lung damage (requiring hospitalisation and often critical care) and death. Currently, systemic corticosteroids alongside the Janus kinase inhibitor baricitinib or an interleukin (IL)-6 receptor blocker are the only drugs strongly recommended by the World Health Organization for the treatment of severe COVID-19 [3]. Mass vaccination programmes using a variety of different COVID-19 vaccines have by now administered >12 billion doses globally [4], but there is still an urgent need for treatments to halt disease progression and enhance recovery from COVID-19.

Viral upper respiratory tract infections commonly trigger exacerbations of asthma and COPD, with the majority of exacerbations linked to the common cold caused by rhinoviruses and coronaviruses, as well as influenza and respiratory syncytial virus [5–8]. Based on existing knowledge of viral respiratory diseases, it was expected that patients with pre-existing chronic lung conditions would be overrepresented among patients hospitalised with COVID-19 and associated with worse outcomes, but this has not transpired [9, 10]. Several, nonmutually exclusive reasons have been suggested that may explain these observations. First, it is possible that respiratory diseases were underdiagnosed or underreported in different countries during the early COVID-19 pandemic, as highlighted in reports from China [11, 12]; second, the dominant airway inflammation associated with the patients’ underlying disease might have provided some protection from...
infection [13, 14]; third, perhaps patients with chronic lung disease behaved more cautiously than the general population early in the COVID-19 pandemic [13, 15], although a survey in France reported that patients with asthma did not behave differently from patients with other chronic diseases [16]; or fourth, treatments used in asthma and COPD, such as inhaled corticosteroids (ICS) may have had a protective effect [11, 13, 15]. In fact, several clinical studies and meta-analyses have suggested that the use of ICS in the treatment of patients with mild or moderate COVID-19 may prevent disease progression [17–22] and may also reduce the risk of disease progression in patients hospitalised due to COVID-19 pneumonia [23].

In this review we summarise the biological, epidemiological and clinical evidence available to date in relation to COVID-19 in patients with asthma or COPD, discuss the association between ICS use and better COVID-19 outcomes, and propose a case for adding ICS to the current armamentarium of treatments for use in COVID-19.

Search strategy

Data for this narrative review were identified by searches of PubMed (https://pubmed.ncbi.nlm.nih.gov), and references from relevant articles, using the following search terms: COVID-19 AND Inhaled Corticosteroid; Coronavirus AND Inhaled Corticosteroid; COVID-19 AND COPD OR Chronic Obstructive Pulmonary Disease; COVID-19 AND Asthma; Coronavirus AND COPD OR Chronic Obstructive Pulmonary Disease; Coronavirus AND Asthma; Inhaled Corticosteroids AND Virus; COVID-19 AND Asthma OR COPD AND Prevalence. Only articles published in English or preprint between January 2020 and March 2022 were included. Additional search terms (non-COVID-19 searches) were Virus AND Exacerbations AND Budesonide/Ciclesonide/Beclomethasone/Mometasone/Flunisolide/Fluticasone; Virus AND Budesonide/Ciclesonide/Beclomethasone/Mometasone/Flunisolide/Fluticasone. Only articles published in English between January 2000 and January 2021 were included.

Basic SARS-CoV-2 biology

SARS-CoV-2 is a single-stranded RNA virus that uses its spike (S) proteins, composed of two subunits (S1 and S2) [24], to enter host cells via angiotensin-converting enzyme 2 (ACE2) [25]. The proposed mechanisms by which SARS-CoV-2 infects cells is shown in figure 1 [25]. ACE2 is expressed in the

![Mechanisms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into cells and potential effects of inhaled corticosteroids (ICS). SARS-CoV-2 binding to membrane-bound angiotensin-converting enzyme 2 (ACE2) leads to type II transmembrane serine protease (TMPRSS2) priming the SARS-CoV-2 spike protein, resulting in its cleavage. This enables the virus to enter the cell via fusion with the cell membrane. Disintegrin and metalloproteinase 17 (ADAM17) can cleave the ectodomain of ACE2, resulting in soluble ACE2, which binds SARS-CoV-2, but does not lead to the virus infecting the cell. The role of ADAM17 in infection is not clear, but it may contribute to fusion of SARS-CoV-2 virus particles with the cell membrane (represented by dashed line arrow). ICS may modify severity of coronavirus disease 2019 infection by downregulating components important for virus attachment and cell entry, such as ACE2 [85, 87, 88], TMPRSS2 [85] and ADAM17 [89]. Reproduced from [25].](https://doi.org/10.1183/16000617.0099-2022)
upper respiratory tract, including the nasal epithelium and the endothelial cells of several organs, and it is also abundantly expressed on alveolar epithelial cells in the lungs [26]. The interactions of ACE2 with the type II transmembrane serine protease (TMPRSS2) and a disintegrin and metalloproteinase 17 (ADAM17) determine virus entry into cells [24, 27].

Lung damage is a result of the cytopathic effects on infected pneumocytes [28, 29], as well as the virus-induced immune response [30], and can include alveolar damage, hyaline membrane formation and pulmonary oedema [29]. In severe cases, SARS-CoV-2 infection is characterised by high serum levels of pro-inflammatory cytokines and chemokines, coupled with a delayed or inadequate interferon response [1]. Infection can cause severe pneumonia leading to acute respiratory distress syndrome (ARDS) [29], resulting in complications that require supportive mechanical ventilation [31]. SARS-CoV-2 can also have systemic effects beyond the lungs, resulting in damage to other organs [32].

**Epidemiology of COVID-19 in patients with asthma and COPD**

A summary of real-world studies investigating the association of asthma and COPD with COVID-19 is presented in table 1 [12, 33–43]. Studies in China, the USA and Ireland, as well as some systematic reviews, have demonstrated that there was either a lower prevalence of asthma among patients with COVID-19, compared with the general population [35, 37], or a prevalence comparable to the general population [40, 41]. In a study in Russia, the prevalence of COPD among patients with COVID-19 was comparable to the general population [33]. Furthermore, in a study conducted in China, the prevalence of asthma and COPD was lower in patients with COVID-19 in comparison to some other comorbidities, such as hypertension and diabetes [12].

Overall, the available evidence indicates that patients with asthma [34–36, 41–44] did not have an increased risk, or had a lower risk, of severe disease, hospitalisation or mortality when infected with SARS-CoV-2, compared with patients without asthma. However, the association is less clear for patients with COPD [42, 45], with a pooled analysis of epidemiological studies showing a significantly reduced relative risk of hospitalisation due to COVID-19 [42] and a systematic review and meta-analysis suggesting that patients with pre-existing COPD have greater than three times the risk of mortality and severe COVID-19 [45]. Other studies also present an inconsistent picture of the risk of worse COVID-19 outcomes with chronic respiratory diseases, although these could be partly explained by differences in the populations studied. For example, in a study in France of hospitalised patients with COVID-19, those with a chronic respiratory disease had an increased risk of severe disease and mortality compared with patients without a chronic respiratory disease [10]. However, in patients with chronic respiratory diseases, the risk of severe COVID-19 was lower than the risk of severe influenza observed in other studies [10]. A study in Spain reported an increase in mortality among patients with asthma and COVID-19, although the comparator population in this retrospective investigation was limited to patients with asthma [38]. Additionally, of note is that in 2020 and early 2021, several studies have observed that the most frequently reported comorbidities associated with hospitalisation and worse outcomes in COVID-19 included hypertension, obesity, diabetes and dyslipidaemia [11, 12, 38, 46]. However, one case series from China reported that chronic respiratory diseases had the third highest case fatality rate after cardiovascular disease and diabetes [47].

**Asthma/COPD biology and COVID-19**

Airway inflammation associated with patients’ underlying chronic respiratory diseases could potentially provide some protection against severe COVID-19. For instance, there may be cross-regulation between the type 2 (T2) immune response in allergic asthma and the interferon-mediated immune response in COVID-19 [14]. Allergic asthma is characterised by the presence of T2 cytokines, some of which can inhibit the production of pro-inflammatory cytokines, and increased numbers of eosinophils (a T2 marker) [48]. Asthma and atopy are also associated with reduced expression of ACE2, which is needed for SARS-CoV-2 to infect cells [49]. A retrospective study of 951 patients with asthma and COVID-19 found that blood eosinophil levels $\geq 150$ cells·$\mu$L$^{-1}$ were associated with a lower likelihood of being admitted to hospital compared with eosinophil levels $<150$ cells·$\mu$L$^{-1}$, and the mortality rate was lower for hospitalised patients whose eosinophil levels increased to $\geq 150$ cells·$\mu$L$^{-1}$ [50]. Another retrospective cohort study of more than 10 000 patients with COVID-19 found that patients with and without asthma and blood eosinophils $\geq 200$ cells·$\mu$L$^{-1}$ had a significantly lower risk of mortality than those with lower eosinophil levels, although it was not reported how many of these patients were on ICS treatment [35, 51]. A registry study including $>46$ 000 patients with COVID-19, however, has demonstrated an association between eosinophil levels and risk for COVID-19 outcomes that varies by ICS treatment. The authors showed that the predicted probability for COVID-19-related hospitalisation, intensive care unit admission or in-hospital mortality was higher among people with eosinophil levels $\geq 150$ cells·$\mu$L$^{-1}$ who were not treated with ICS,
| Study            | Study design     | Location     | Cohort                                      | Setting                          | Results                                                                                                                                 |
|------------------|------------------|--------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Guan et al. [12] | Observational    | China        | COVID-19 positive; n=1590                   | Hospital                         | Lower prevalence of COPD (1.5%) and asthma (0%) versus other comorbidities – hypertension (16.9%) and diabetes (8.2%)               |
| Avdeev et al. [33]| Observational    | Russia       | COVID-19 (positive or pending with severe acute respiratory infection and typical CT); n=1307 | ICU                              | Low prevalence of bronchial asthma (1.8%) and COPD (3.1%), not higher than in the general population                                     |
| Robinson et al. [34] | Observational | USA          | COVID-19 positive; n=866                   | Hospital                         | Hazard ratio 0.52 (95% CI 0.30–0.90) for ICU admission and 0.42 (95% CI 0.21–0.81) for mechanical ventilation for patients with asthma versus patients without asthma |
| Ho et al. [35]   | Observational    | USA          | COVID-19 positive; n=10 523                | Hospital inpatient and outpatient | Odds ratio 0.43 (95% CI 0.28–0.64) for hospitalisation, 0.51 (95% CI 0.41–0.64) for ICU admission and 0.64 (95% CI 0.53–0.77) for mortality for patients with asthma versus patients without asthma |
| Cao et al. [36]  | Observational    | USA          | COVID-19 positive; n=343                   | Medical centre                   | Odds ratio 1.00 (95% CI 0.34–3.28) for hospitalisation, 0.59 (95% CI 0.31–1.08) for ICU admission, 1.10 (95% CI 0.56–2.12) for mechanical ventilation, 0.73 (95% CI 0.30–1.64) for in-hospital mortality due to COVID-19 for patients with asthma versus patients without asthma |
| Li et al. [37]   | Observational    | China        | COVID-19 positive; n=548                   | Hospital                         | Low proportion of patients with COVID-19 who had asthma (0.9%)                                                                         |
| Izquierdo et al. [38] | Observational | Spain        | Asthma; n=71 182                           | EHRs: primary care, hospital inpatient, outpatient, emergency department | Odds ratio 2.29 (95% CI 4.35–6.66) for mortality for patients with asthma and COVID-19 versus patients with asthma without COVID-19 |
| Choi et al. [39] | Observational    | South Korea  | COVID-19 positive; n=7590                  | Medical claims (including hospital inpatient and outpatient) | Patients with step 5 (more severe) asthma had a more prolonged stay in hospital versus patients with step 1 asthma                  |
| Butler et al. [40] | Observational   | Ireland      | COVID-19 positive; n=193                   | Hospital                         | Prevalence of asthma (8.8%) versus general population (7.0%)                                                                         |
| Sunjari et al. [41] | Systematic review | Multiple countries | COVID-19 positive; n=349 592 overall, n=369 405 for risk ratio reduction analysis | Primary care, hospital, mixed | Prevalence of asthma was 7.46% (95% CI 6.25–8.67). Showed a 14% (95% CI 0.80–0.94) and 13% (95% CI 0.77–0.99) risk ratio reduction for acquiring and being hospitalised for COVID-19, respectively, for patients with asthma versus no asthma |
| Rogliani et al. [42] | Systematic review | Multiple countries | COVID-19 positive; n=8476                  | Hospital                         | Relative risk of hospitalisation reduced in patients with asthma (0.86, 95% CI 0.77–0.97) and COPD (0.46, 95% CI 0.40–0.52) versus general population |
| Liu et al. [43]  | Systematic review | Multiple countries | COVID-19; n=410 382 overall, n=5000 for risk ratio analysis | Nonhospital, hospital, ICU       | Risk ratio 0.65 (95% CI 0.43–0.98) for mortality for patients with asthma versus patients without asthma                                |

CT: computed tomography; EHR: electronic health record; ICU: intensive care unit.
but not among those who were [52]. In contrast, studies have found that a greater severity of airflow limitation in patients with COPD (regardless of smoking status) is related to higher expression of ACE2, which could increase the susceptibility of these patients to SARS-CoV-2 infection [53, 54].

**Antiviral effects of ICS**

**Common cold viruses**

ICS are frequently used in the treatment of patients with asthma and COPD in combination with bronchodilators [55, 56]. Multiple studies have shown that ICS, in combination with long-acting β₂-agonists, is an effective treatment for reducing virus-induced asthma exacerbations [57, 58]. Evidence for the importance of ICS in this combination supports its potential to alleviate the effects of SARS-CoV-2 infection in the lungs [59, 60]. For instance, ICS use has previously been found to be protective against hospitalisation for rhinovirus-induced asthma exacerbations [60]. Furthermore, a retrospective study of more than 12,000 patients with asthma, which investigated different regimens of asthma treatments on reducing common cold-related severe exacerbations, found that the dosage and/or timing of ICS administration was an important factor influencing the risk of cold-related exacerbations [59].

*In vitro* studies suggest mechanisms for how ICS (and β₂-agonists) might act on cells of the lungs to reduce exacerbations caused by common cold viruses. Budesonide and formoterol have been shown to reduce type 14 rhinovirus-induced pro-inflammatory cytokine release and inhibit viral RNA replication in human tracheal epithelial cells [61]. A budesonide/glycopyrronium/formoterol combination inhibited human coronavirus-induced pro-inflammatory cytokine production and virus replication in primary human nasal and tracheal epithelial cells [62]. Another study showed that budesonide and formoterol, as well as budesonide alone, inhibited rhinovirus-induced chemokines in primary normal human bronchial epithelial (NHBE) cells [63]. Additionally, fluticasone propionate and budesonide have both been shown to inhibit viral mimic poly-(I:C)-induced chemokine release in the cell line 16HBE and human primary bronchial epithelial cells, fluticasone propionate inhibited respiratory syncytial virus-induced chemokine release in the cell line BEAS-2B and fluticasone propionate alone or with salmeterol inhibited rhinovirus-induced cytokine release, also from BEAS-2B cells and from NHBE cells [64–66].

**ICS use in patients with COVID-19**

Potential protective effects of ICS on COVID-19 outcomes in patients with asthma or COPD have been observed. In a retrospective study of 71,182 patients with asthma, in Spain, fewer patients who were hospitalised for COVID-19 were ICS users, versus nonhospitalised patients [38]. A retrospective study in South Korea found that the use of ICS by patients with asthma tended to be associated with a reduced risk of COVID-19, although this was not statistically significant [67]. Another retrospective study, in Israel, showed that ICS use in patients with mild bronchial asthma did not have any impact on whether they tested positive for COVID-19 [68]. A retrospective study in Denmark found that there were no positive or negative effects of existing ICS use on intensive care admission or mortality, in patients hospitalised with SARS-CoV-2 infection, although a sensitivity analysis suggested that budesonide use was associated with a reduced risk of severe COVID-19 outcomes relative to use of fluticasone, compared with no ICS use or use of bronchodilators [69]. A retrospective study in the UK showed that among over 65,000 patients ≥50 years of age who were hospitalised for COVID-19, there was a reduced mortality risk for those with asthma (but not for those with COPD) who were using ICS within 2 weeks of admission [70]. However, a limitation of this study was that asthma severity status was based solely on medication history. Conversely, in the large observational OpenSAFELY study in the UK, the risk of COVID-19-related death was reported to be higher in patients with asthma or COPD who were using ICS compared with those using other noncorticosteroid respiratory medications, albeit again this study was not able to account for differences in underlying disease severity [71, 72]. Additionally, a retrospective chart review of 787 patients with asthma hospitalised for symptomatic COVID-19 showed that patients already on ICS were 1.6 times more likely to be discharged on oxygen than patients not on ICS, though whether this reflected underlying asthma severity or use of ICS is not clear [73]. Another retrospective, observational study including 275 hospitalised COVID-19 patients with asthma reported that the number of days on ventilation was significantly increased in patients already receiving ICS therapy versus those who were not; however, being on ICS therapy at admission did not alter overall COVID-19 severity, disease complications or mortality [74]. These studies and their findings highlight the difficulties in accounting for the heterogeneity in underlying respiratory disease and disease severity when investigating the benefits of ICS in COVID-19 in the real world. Furthermore, the use of oral rescue packs (e.g. oral corticosteroids) by patients with asthma or COPD who develop COVID-19 symptoms is also a consideration in the interpretation of the real-world data for any benefit of ICS, although this does not impact results of some of the randomised, clinical trials as the authors specify recent inhaled or systemic glucocorticoids as an exclusion criterion [17, 18, 23].

https://doi.org/10.1183/16000617.0099-2022
The first randomised clinical trial to examine the effect of ICS in patients with COVID-19 was the phase II Steroids in COVID-19 (STOIC) proof-of-concept study, which examined the effect of inhaled budesonide in early COVID-19 in adults aged 18 and over [17]. Using daily home monitoring, the study showed that inhaled budesonide (800 µg twice daily) within 7 days of onset of mild COVID-19 symptoms reduced the likelihood of needing urgent care (including emergency department assessment or hospitalisation) by 91% (relative risk reduction) and reduced self-reported recovery time by 1 day, compared with usual care. The median time to resolution of symptoms (measured by the Influenza Patient-Reported Outcome questionnaire), was numerically improved by 1 day with budesonide treatment versus usual care. Additionally, a significantly greater proportion of patients was symptom free after 14 days with budesonide treatment. There was no change in viral load at the end of the 28-day treatment period. The Platform Randomised trial of INterventions against COVID-19 In older peoople (PRINCIPLE) study was a phase III clinical platform study in the UK [18]. The PRINCIPLE patient population included individuals ≥65 years old (or ≥50 years with underlying health conditions) who were randomised to receive inhaled budesonide (800 µg twice daily) within 14 days of COVID-19 symptoms or a positive test, or standard care. The results showed that recovery time was on average 3 days shorter and hospital admissions or deaths were 2% lower in patients receiving inhaled budesonide compared with patients receiving standard care, although this result did not meet the prespecified superiority threshold. Secondary outcomes in PRINCIPLE showed evidence of reduced time to sustained alleviation of all symptoms, as well as shortened time to initial reduction of symptom severity with budesonide treatment versus usual care. The phase IV investigator-initiated, open-label TACTIC trial recruited adults aged 18–80 in Argentina and Spain, hospitalised with COVID-19 pneumonia [23]. The study investigated the effects of the addition of inhaled budesonide to standard care, compared with standard care alone, on disease progression (a composite variable including the initiation of treatment with high-flow oxygen therapy, noninvasive or invasive ventilation, and/or death) at day 15 after starting treatment. Although the study was terminated early and lacked statistical power, the results suggested that inhaled budesonide (400 µg twice daily) in addition to standard care has a favourable safety profile and may reduce the risk of disease progression [23]. A randomised, open-label phase II trial to evaluate the efficacy of ciclesonide treatment for 14 days versus standard care showed that inhaled ciclesonide shortened viral shedding duration and may inhibit progression to acute respiratory failure in patients with mild-to-moderate COVID-19 [22]. However, an open-label phase III study to assess the efficacy of inhaled ciclesonide in reducing the risk of adverse outcomes in COVID-19 patients at risk of developing severe illness demonstrated insufficient evidence that ICS are beneficial for people with COVID-19 [75]. A phase III study in the USA that investigated the safety and efficacy of inhaled ciclesonide on nonhospitalised patients aged 12 and over with symptomatic COVID-19 showed that there was no difference in the time to alleviation of COVID-19-related symptoms with inhaled ciclesonide (320 µg twice daily for 30 days) compared with placebo [19]. However, patients who received ciclesonide had fewer emergency department visits or hospital admissions for reasons related to COVID-19 [19].

In May 2021, the European Medicines Agency COVID-19 Taskforce reviewed evidence for the treatment of outpatients with COVID-19 [17–19] and concluded that it was insufficient to show a benefit of ICS in people with COVID-19 [76]. A meta-analysis including data from STOIC [17], PRINCIPLE [18], the phase III US study [19] and CONTAIN, a Canadian, placebo-controlled trial of inhaled ciclesonide in adult outpatients with COVID-19 [77], compared the outcome of hospitalisation and showed a promising effect of ICS in preventing hospitalisation [20]. It was noted, however, that STOIC included a composite outcome of urgent care visits and hospitalisation; therefore, the effect on urgent care visits may have exaggerated the estimated effect on hospitalisations. Furthermore, potential bias was highlighted of unblinded providers being more likely to refer to urgent care when a patient was not on treatment [20]. A Cochrane review of ICS for the treatment of COVID-19 found moderate-certainty evidence that ICS versus standard care of ICS in people with asymptomatic/mild COVID-19 probably reduces admission to hospital or death, and increases the resolution of all initial symptoms at day 14 [21]. The authors noted that the evidence identified came from studies in high-income settings – STOIC, PRINCIPLE and the phase III US study – prior to vaccination rollout and emergence of newer variants (delta, omicron) of SARS-CoV-2, yet assume no relevant effect on expected benefits and harms of ICS [21]. Details of ongoing, or recently completed but currently unpublished (as of March 2022), prospective randomised clinical trials investigating ICS therapy in SARS-CoV-2 infection are shown in table 2 [78–84].

There are several different, nonmutually exclusive mechanisms by which ICS could potentially modify the severity of COVID-19 infection. Firstly, they may prevent SARS-CoV-2 infection by downregulating components important for virus attachment and cell entry (figure 1), as ICS use has been associated with lower expression of ACE2 and TMPRSS2 [85]. The ACE2 gene can be stimulated by interferon [86], and a study reported that ICS downregulated ACE2 expression, through suppression of type I interferon in
| Trial no.            | Name            | Treatment                                                                 | Setting         | Primary outcome                                                                 | n (planned) | Start date       | Estimated or actual primary completion date | Location |
|---------------------|-----------------|---------------------------------------------------------------------------|-----------------|--------------------------------------------------------------------------------|-------------|------------------|--------------------------------------------|----------|
| JPRN-JRCTs031190269 | RACCO           | Ciclesonide 400 µg three times daily for 7 days                         | Hospital        | Incidence of pneumonia on day 8 following treatment                             | 90          | April 2020       | October 2020                               | Japan    |
| NCT04381364 [84]    | HALT COVID-19   | Ciclesonide 320 µg twice daily for 14 days versus standard care          | Hospital        | Duration (days) of received supplemental oxygen therapy within 30 days after study inclusion | 446         | May 2020         | August 2021                               | Sweden   |
| EudraCT 2020-002208-37 | CIMMCov        | Ciclesonide 320 µg twice daily for 28 days versus placebo                | Primary care    | Reduction in healthcare resource utilisation (renewed contact with GP, emergency department and/or admission to hospital) due to COVID-19-related symptoms | 138         | June 2020        | Ongoing*                                   | Denmark  |
| CTRI/2020/10/028581 | Budesonide Rotacaps 200 µg twice daily for 10–14 days in addition to standard care versus standard care alone | Primary care | Hospitalisation                                                               | 1000        | October 2020     | December 2020                             | India    |
| CTRI/2021/05/033817 | Budesonide 400 µg (two puffs twice daily) for up to 28 days versus standard care alone | Primary care | Hospitalisation or emergency department attendance related to COVID-19     | 820         | May 2021*        | Unknown                                    | India    |
| NCT04937543 [81]    | TRIVID          | Beclomethasone 250 µg or beclomethasone/formoterol/glycopyrronium 100/6/12.5 µg (two doses twice daily) for 28 days in addition to standard care versus standard care alone | Primary care | Use of healthcare resources 28 days after treatment                            | 260         | June 2021        | October 2021                              | Brazil   |
| NCT05054322 [82]    | FLOT            | Fluticasone propionate 125 µg with spacer (four puffs twice daily) for 14 days in addition to standard care | Primary care    | Incidence of adverse outcomes (oxygen therapy, systemic corticosteroids, hospitalisation, mechanical ventilation and mortality) in symptomatic patients at 28 days after study inclusion | 500         | September 2021   | January 2022                              | Vietnam  |

*: Trial ongoing as of 11 January 2022 (date accessed). #: Date on which this record was first entered in the EudraCT database. *: Date of first enrolment (India). GP: general practitioner.
airway epithelial cells from patients with COPD [87]. In addition, fluticasone propionate, an ICS that is also used intranasally, has been shown to suppress viral mimic-induced ACE2 gene and protein expression in primary human nasal epithelial cells [88]. Downregulation of ADAM17 gene expression has also been reported in association with ICS, although the implication for SARS-CoV-2 infection is unclear [89]. Secondly, some ICS have shown antiviral activity against SARS-CoV-2 in vitro. One in vitro study demonstrated that the ICS ciclesonide had antiviral activity against SARS-CoV-2 [90] and in another study, some but not all ICS therapies blocked SARS-CoV-2 replication in vitro, a finding that warrants further investigation [91]. Another study found that budesonide had an antiviral effect against SARS-CoV-2 wild-type strain B1.1.70 and two variants, B.1.1.7 (alpha) and B1.351 (beta), in vitro [92]. Thirdly, in asthma, ICS reduce airway inflammation by suppressing gene transcription of inflammatory cytokines and by inhibiting recruitment of inflammatory cells [93], so they can potentially prevent the hyperinflammation seen in SARS-CoV-2 infection, as mechanistic modelling has indicated [94]. A study assessing inflammatory mediators in the nasal mucosa and blood of patients from the STOIC clinical trial and a SARS-CoV-2-negative cohort provided a mechanistic insight into the effects of inhaled budesonide on early COVID-19 infection and how this could lead to shortened recovery time in patients treated with budesonide [95]. It was found that there was a distinctive nasal inflammatory response in early COVID-19, comprising a combined type I and type II interferon response and a type 1 (T1) and T2 cytokine- and chemokine-mediated response [95, 96]. Early administration of budesonide was found to attenuate inflammation by significantly suppressing IL-33 and interferon-γ, suggesting a dampening of the interferon response and reduced epithelial damage. Furthermore, the chemokine CCL17 was significantly elevated, suggesting an improved T-cell response [95]. Finally, a study showed that ICS given to patients at risk of developing ARDS improved blood oxygenation and reduced this risk, although inhaled β-agonists may have also played a role in this setting [97].

**Clinical practice considerations**

The availability of effective SARS-CoV-2 vaccines was a key step forward in our fight against the pandemic, but we still need effective therapies for individuals who develop COVID-19. The lungs are the main site of the effects of SARS-CoV-2 infection and the use of ICS in respiratory disease to directly target the lungs is well established. Available evidence reviewed here indicates that the use of ICS – specifically budesonide or ciclesonide – can improve outcomes of COVID-19. However, on the basis of evidence from the STOIC [17] and PRINCIPLE [18] trials, guidance has been issued in the UK that ICS (specifically budesonide) are only recommended to treat COVID-19 as part of a clinical trial, although should not be discontinued if a patient is already on treatment. Although the benefit of inhaled budesonide in reducing time to recovery from COVID-19 was acknowledged, evidence was considered limited as STOIC was terminated early and did not meet the target sample size. Furthermore, as study populations included primarily older people, the results are not generalisable to other age groups [98]. However, inhaled budesonide or ciclesonide is recommended as a treatment to consider for mild COVID-19 in Canada (British Columbia), and inhaled budesonide in India, Russia and Saudi Arabia [99–102].

The worldwide availability and affordability of ICS (budesonide is on the World Health Organization’s list of essential medicines [103]), including in generic form, facilitates their use where there are regional disparities in the management of the COVID-19 pandemic. This is especially important in regions with less advanced vaccination programmes, less developed healthcare resources and where there is concern with SARS-CoV-2 variants and reduced vaccine efficacy.

There are indications that more severe and symptomatic initial COVID-19 infection is associated with an increased likelihood of experiencing COVID-19 sequelae – ‘long COVID’ [104], although further studies are needed [105, 106]. ICS may benefit patients with early symptoms by acting on the inflammation evident at the start of infection and by inhibiting viral replication. Managing infection as early as possible has the potential to reduce the incidence of these sequelae, as both the STOIC [17] and PRINCIPLE [18] studies have shown lower symptom persistence in volunteers taking budesonide compared with the standard of care, although both studies were of short (28 days) duration. From the observations of the positive effects of ICS in COVID-19 studies to date, it is possible that they could have a beneficial effect on long-term respiratory outcomes, such as on the impaired lung function associated with COVID-19 sequelae, which warrants investigation.

Additional studies are necessary to determine which of the available ICS compounds may be more likely to reduce the severity of COVID-19, since it is acknowledged that ICS may not all have beneficial effects. For example, there is evidence from a sensitivity analysis of ICS subtypes in a retrospective study of hospitalised patients that budesonide may be associated with a reduced risk of severe COVID-19 outcomes.
relative to fluticasone, compared with no ICS use [69] and an in vitro study demonstrated that ciclesonide and mometasone suppressed SARS-CoV-2 replication, whereas fluticasone did not [91].

Ongoing review of the outcomes of ICS use in patients with COVID-19 is vital to understand if the effect of ICS varies between different strains of SARS-CoV-2 or differs in vaccinated versus unvaccinated individuals. What we learn from the effect of ICS on COVID-19 severity will also be crucial in preparation for future pandemics, and the lessons learned could be extended to other viral upper respiratory tract infections in asthma and COPD. While it has been recommended that patients who use ICS should continue to do so [55, 56], it is also important to further investigate ICS use to provide clinicians with clear evidence-based information to relay to patients with chronic lung disease who are concerned about potential increased risk to their health during the pandemic [107]. Further studies investigating the efficacy of ICS in the prevention and treatment of severe disease are also needed. Of note, adverse events such as the onset of diabetic ketoacidosis have been reported in patients with type 2 diabetes mellitus following the use of dexamethasone to treat COVID-19 [108]. As diabetes is one of the most prevalent comorbidities in COVID-19 patients, the early use of ICS to limit infection and reduce the requirement for systemic corticosteroids could reduce the risk of such adverse events in many patients with COVID-19.

To conclude, ICS could potentially benefit COVID-19 infected patients, particularly high-risk groups, if used ideally within days of symptoms starting. As the side effects of ICS are well known and reversible upon cessation, their favourable benefit-to-risk profile would suggest that ICS are a worthwhile consideration for treatment of COVID-19.

Provenance: Submitted article, peer reviewed.

Acknowledgements: The authors would like to thank Per Gustafson (AstraZeneca, Gothenburg, Sweden) for his contribution to the outline.

Conflict of interest: M. Bafadhel has unrestricted research grants from AstraZeneca and Roche, and has received honoraria to her institution for speaker’s fees from AstraZeneca, Chiesi, Cipla and GlaxoSmithKline. She is a scientific adviser to Albus Health and ProAxsis. R. Faner has received research funding, advisory board fees and lecture fees from AstraZeneca, Chiesi, GlaxoSmithKline and Menarini. C. Taillé has received grants to her institution, advisory board fees and lecture fees from AstraZeneca, Chiesi, GlaxoSmithKline, Novartis and Sanofi. R.E.K. Russell has received advisory board fees and lecture fees from AstraZeneca, Chiesi, Cipla and GlaxoSmithKline. T. Welte has received lecture fees from AstraZeneca, Basilea, Bayer, Berlin Chemie, Biotest, Boehringer Ingelheim, GlaxoSmithKline, MSD, Novartis, Pfizer, Roche and Sanofi-Aventis, and advisory board fees from AstraZeneca, Basilea, Bayer, Biotest, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer and Roche. P.J. Barnes has received research funding from AstraZeneca and Boehringer Ingelheim, and funding for consultancy, scientific advisory boards and talks from AstraZeneca, Boehringer Ingelheim, Covis, Epi-Endo, Novartis, Pfizer and Teva. A. Agustí has unrestricted research grants from AstraZeneca and GlaxoSmithKline, and has received honoraria for speaker’s fees from AstraZeneca, Chiesi, GlaxoSmithKline, Menarini, Orion Pharma and Zambon.

Support statement: Medical writing support, under the direction of the authors, was provided by Sharon Gill, PhD, CMC Connect, a division of IPG Health Medical Communications and was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines [109]. Funding information for this article has been deposited with the Crossref Funder Registry.

References
1 Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol 2021; 21: 245–256.
2 World Health Organization. Coronavirus disease (COVID-19) pandemic. www.who.int/emergencies/diseases/novel-coronavirus-2019 Date last updated: 14 September 2022. Date last updated: 15 September 2022.
3 World Health Organization. Therapeutics and COVID-19: living guideline. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5 Date last updated: 16 September 2022. Date last accessed: 4 November 2022.
4 Our World in Data. Coronavirus (COVID-19) vaccinations. https://ourworldindata.org/covid-vaccinations Date last updated: 28 October 2022. Date last accessed: 4 November 2022.
5 Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations—a GA² LEN-DARE systematic review. Allergy 2011; 66: 458–468.
Guan W-J, Liang W-H, Zhao Y, Heffler E, Detoraki A, Contoli M, Halpin DMG, Faner R, Sibila O, Yu L-M, Bafadhel M, Dorward J, Ramakrishnan S, Nicolau DV, Langford B, Nicolau DV, Bafadhel M. Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?

Rohde G, Wiethege A, Borg I, Seemungal T, Harper-Owen R, Bhowmik A, Robinson LB, Fu X, Bassett IV, et al. COVID-19 severity in hospitalized patients with asthma: A matched cohort study. J Allergy Clin Immunol Pract 2021; 9: 497–500.

Lee TC, Bortolussi-Courval É, Belga S, et al. Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis. Eur Respir J 2022; 59: 2102921.

Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2022; 3: CD015125.

Song JY, Yoon JG, Seo YB, et al. Ciclesonide inhaler treatment for COVID-19: a randomised, open-label, phase 2 trial. J Clin Med 2021; 10: 3545.

Agusti A, De Stefano G, Levi A, et al. Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. Eur Respir J 2022; 59: 2103036.

Ragia G, Manolopoulos VG. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur J Clin Pharmacol 2020; 76: 1623–1630.

Xiaol, Sakagami H, Miwa N. ACE2: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? Viruses 2020; 12: 109055.

Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631–637.

Zipeto D, Palmeira JDF, Arganaraz GA, et al. ACE2/ADAM17/TMPRSS2 interplay may be the main risk factor for COVID-19. Front Immunol 2020; 11: 576745.

Mlay A, Konda B, Garcia G, et al. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. Cell Rep 2021; 35: 109055.

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420–422.

Welte T. SARS-CoV-2-triggered immune reaction: for COVID-19, nothing is as old as yesterday’s knowledge. Am J Respir Crit Care Med 2021; 203: 156.

Lepper PM, Muellenbach RM. Mechanical ventilation in early COVID-19 ARDS. EclinicalMedicine 2020; 28: 100616.

Sridhar S, Nicholls J. Pathophysiology of infection with SARS-CoV2—what is known and what remains a mystery. Respirology 2021; 26: 652–665.

Avdeev S, Moiseev S, Brovkó M, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy 2020; 75: 2703–2704.
Ho KS, Howell D, Rogers L, et al. The relationship between asthma, eosinophilia, and outcomes in coronavirus disease 2019 infection. Ann Allergy Asthma Immunol 2021; 127: 42–48.

Cao L, Lee S, Krings JG, et al. Asthma in patients with suspected and diagnosed coronavirus disease 2019. Ann Allergy Asthma Immunol 2021; 126: 535–541.

Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146: 110–118.

Izquierdo JL, Almonacid C, González Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J 2021; 57: 2003142.

Choi YJ, Park JY, Lee HS, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J 2021; 57: 2002226.

Butler MW, O’Reilly A, Dunican EM, et al. Prevalence of comorbid asthma in COVID-19 patients. J Allergy Clin Immunol 2020; 146: 334–335.

Sunjaya AP, Allida SM, Di Tanna GL, et al. Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: systematic review and meta-analysis. J Asthma 2022; 59: 866–879.

Rogliani P, Lauro D, Di Daniele N, Rabbani G, Shariful Islam SM, Rahman MA, Sitek AN, Ade JM, Chiarella SE, Liu S, Cao Y, Du T, Cao L, Lee S, Krings JG, Li X, Xu S, Yu M, Choi YJ, Park JY, Lee HS, Ng WH, Tipih T, Makoah NA, Butler MW, O’Reilly A, Dunican EM, et al. Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: a rapid systematic review and meta-analysis. Expert Rev Respir Med 2021; 15: 705–716.

Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio 2021; 12: e03647-20.

Epidemiology Group of the New Corona Virus Pneumonia Emergency Response Mechanism of the Chinese Center for Disease Control and Prevention. Epidemiological analysis of new coronavirus pneumonia. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41: 145–151.

Liu S, Zhi Y, Ying S. COVID-19 and asthma: reflexion during the pandemic. Clin Rev Allergy Immunol 2020; 59: 78–88.

Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020; 146: 203–206.

Ferstraatoarui D, Hudes G, Jerschow E, et al. Eosinophilia in asthma patients is protective against severe COVID-19 Illness. J Allergy Clin Immunol Pract 2021; 9: 1152–1162.

Ramakrishnan S, Bafadhel M. Eosinophilic inflammation, coronavirus disease 2019, and asthma: are inhaled corticosteroids the missing link? Ann Allergy Asthma Immunol 2021; 127: 278.

Zein JG, Strauss R, Attaway AH, et al. Eosinophilia is associated with improved COVID-19 outcomes in inhaled corticosteroid-treated patients. J Allergy Clin Immunol Pract 2022; 10: 742–750.e14.

Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55: 2000688.

Agusti A, Sibila O, Casas-Recasens S, et al. Molecular interactions of SARS-CoV-2 in lung tissue of patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 2021; 18: 1922–1924.

Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2022. Available from: https://ginasthma.org/gina-reports Date last updated: 3 May 2022. Date last accessed: 4 November 2022.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. 2021. Available from: https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf Date last updated: 22 November 2021. Date last accessed: 4 November 2022.

Stolz D, Hirsch HH, Schilte & et al. Intensified therapy with inhaled corticosteroids and long-acting β2-agonists at the onset of upper respiratory tract infection to prevent chronic obstructive pulmonary disease exacerbations. A multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2018; 197: 1136–1146.

Prazma CM, Kral KM, GuI N, et al. Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections. Respir Med 2010; 104: 780–787.

Reddel HK, Jenkins C, Quirce S, et al. Effect of different asthma treatments on risk of cold-related exacerbations. Eur Respir J 2011; 38: 584–593.

Venarske DL, Busse WW, Griffin MR, et al. The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking. J Infect Dis 2006; 193: 1536–1543.

Yamaya M, Nishimura H, Nadine L, et al. Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells. Respir Investig 2014; 52: 251–260.
Heijink IH, Jonker MR, de Vries M, Schultze A, Walker AJ, MacKenna B, Noah TL, Wortman IA, Becker S. The effect of fluticasone propionate on respiratory syncytial virus-induced airway epithelial barrier. *Respir Res* 2016; 17: 2.

Noah TL, Wortman IA, Becker S. The effect of fluticasone propionate on respiratory syncytial virus-induced chemokine release by a human bronchial epithelial cell line. *Immunopharmacology* 1998; 39: 193–199.

66 Edwards MR, Johnson MW, Johnston SL. Combination therapy: synergistic suppression of virus-induced chemokines in airway epithelial cells. *Am J Respir Cell Mol Biol* 2006; 34: 616–624.

67 Choi JC, Jung S-Y, Yoon UA, et al. Inhaled corticosteroids and COVID-19 risk and mortality: a nationwide cohort study. *J Clin Med* 2020; 9: 3406.

68 Green I, Merzon E, Vinker S, et al. COVID-19 susceptibility in bronchial asthma. *J Allergy Clin Immunol Pract* 2021; 9: 684–692.

69 Husby A, Pottegard A, Hviid A. Association between inhaled corticosteroid use and COVID-19 outcomes. *Pharmacoepidemiol Drug Saf* 2021; 30: 1486–1492.

70 Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre, prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. *Lancet Respir Med* 2021; 9: 699–711.

71 Schulze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. *Lancet Respir Med* 2020; 8: 1106–1106.

72 Singh D, Halpin DMG. Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? *Lancet Respir Med* 2020; 8: 1065–1066.

73 Farzan S, Rebaza A, Rai S, et al. An analysis of demographics and inhaled corticosteroid use on COVID-19 outcomes among hospitalized adult asthmatics: an early experience at a NY hospital system. *J Asthma Allergy* 2021; 14: 1473–1484.

74 Alakeel YS, Alharbi EF, Alhaaidal HA, et al. The effects of the antecedent use of inhaled steroid on the clinical course of COVID-19: a retrospective study of asthmatic patients. *J Infect Public Health* 2022; 15: 56–64.

75 Duvignaud A, Lhomme E, Onaïsi R, et al. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). *Clin Microbiol Infect* 2022; 28: 1010–1016.

76 European Medicines Agency. Insufficient data on use of inhaled corticosteroids to treat COVID-19. www.ema.europa.eu/en/news/insufficient-data-use-inhaled-corticosteroids-treat-covid-19. Date last updated: 27 May 2021. Date last accessed: 4 November 2022.

77 Ezer N, Belga S, Daneman N, et al. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. *BMJ* 2021; 375: e068060.

78 Clinical Trials Registry – India. Clinical trial to study the effect of budesonide taken through inhalation in mild COVID cases (CTR/2020/10/028581). www.ctr.nic.in/clinicaltrials/pdfs_generate.php?trialid=47042&EncHid=&&compid=%27%27%27%27%27%27%27%27%27%27%27 Date last accessed: 4 November 2022.

Clinical Trials Registry – India. Use of steroid inhalers in COVID (CTR/2021/05/033817). http://ctr.nic.in/clinicaltrials/pdfs_generate.php?trialid=48544&EncHid=&&compid=%27%27%27%27%27%27%27%27%27%27%27 Date last accessed: 4 November 2022.

80 EU Clinical Trials Register. CIMMCov: a randomized, clinical study for prevention of severe disease in mild-to-moderate COVID-19 patients, using the inhaled medication ciclesonide (EudraCT 2020-002208-37). www.clinicaltrialsregister.eu/ctr-search/trial/2020-002208-37/ DK Date last accessed: 4 November 2022.

81 Clinical Trials.gov. Efficacy of inhaled therapies in the treatment of acute symptoms associated with COVID-19 (TRIVID) (NCT04937543). www.clinicaltrials.gov/ct2/show/NCT04937543 Date last accessed: 4 November 2022.

82 Clinical Trials.gov. FLuticasone in cOvid Treatment (FLOT) (NCT05054322). https://clinicaltrials.gov/ct2/show/NCT05054322 Date last accessed: 4 November 2022.

83 Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. *Am J Respir Crit Care Med* 2020; 202: 83–90.

https://doi.org/10.1183/16000617.0099-2022
Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020; 181: 1016–1035.e19.

Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol 2021; 147: 510–519.e5.

Nakazono A, Nakamaru Y, Ramezanpour M, et al. Fluticasone propionate suppresses poly(I:C)-induced ACE2 in primary human nasal epithelial cells. Front Cell Infect Microbiol 2021; 11: 655666.

Milne S, Li X, Yang CX, et al. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial. Eur Respir J 2021; 58: 2100130.

Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 2020; 64: e00819-20.

Matsuyma S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol 2020; 95: e01648-20.

Heinen N, Meister TL, Klohn M, et al. Antiviral effect of budesonide against SARS-CoV-2. Viruses 2021; 13: 1411.

Barnes PJ. Inhaled corticosteroids. Pharmaceuticals 2010; 3: 514–540.

Fadai NT, Sachak-Patwa R, Byrne HM, et al. Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. J R Soc Interface 2021; 18: 20200950.

Baker JR, Mahdi M, Nicolau DV, et al. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respir Med 2022; 10: 545–556.

Liew F, Openshaw PJ M. Inhaled corticosteroids: not just for asthma, but for COVID-19? Lancet Respir Med 2022; 10: 526–527.

Festic E, Carr GE, Cartin-Ceba R, et al. Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome. Crit Care Med 2017; 45: 798–805.

National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. www.nice.org.uk/guidance/NG191 Date last updated: 14 July 2022.

British Columbia COVID-19 Therapeutics Committee and COVID-19 Therapeutics Review and Advisory Working Group. Antimicrobial and immunomodulatory therapy in adult patients with COVID-19. www.bccdc.ca/health-professionals/clinical-resources/covid-19-care/clinical-care/treatments Date last updated: 2 November 2022. Date last accessed: 4 November 2022.

Ministry of Health and Family Welfare Government of India. Clinical guidance for management of adult COVID-19 patients. https://covid.aiims.edu/wp-content/uploads/2021/04/COVID_Management_Algorithm_170521.pdf Date last updated: 17 May 2021. Date last accessed: 4 November 2022.

Saudi Ministry of Health. Saudi MoH protocol for patients suspected of/confirmed with COVID-19. www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf Date last updated: 29 September 2022. Date last accessed: 4 November 2022.

Ministry of Health of the Russian Federation. Temporary methodological recommendations: prevention, diagnostics and treatment of new coronavirus infections (COVID-19). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/B%20%09%20%0A_COVID-19.pdf Date last updated: 7 May 2021. Date last accessed: 4 November 2022.

World Health Organization. Model List of Essential Medicines. https://list.essentialmeds.org/ Date last accessed: 4 November 2022.

National Institute for Health and Care Excellence. NICE, SIGN and RCGP set out further details about the UK guideline on management of the long-term effects of COVID-19. www.nice.org.uk/news/article/nice-sign-and-rcgp-set-out-further-details-about-the-uk-guideline-on-management-of-the-long-term-effects-of-covid-19 Date last updated: 30 October 2020. Date last accessed: 4 November 2022.

Iqbal FM, Lam K, Sounderajah V, et al. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EclinicalMedicine 2021; 36: 100899.

Sibila O, Albacar N, Perea L, et al. Lung function sequelae in COVID-19 patients 3 months after hospital discharge. Arch Bronconeumol 2021; 57: 59–61.

Russell R. COVID-19 and COPD: a personal reflection. Int J Chron Obstruct Pulmon Dis 2020; 15: 883–884.

Mondal S, DasGupta R, Lodh M, et al. Predictors of new-onset diabetic ketoacidosis in patients with moderate to severe COVID-19 receiving parenteral glucocorticoids: a prospective single-centre study among Indian type 2 diabetes patients. Diabetes Metab Syndr 2021; 15: 795–801.

Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med 2015; 163: 461–464.